Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 303 | 831 | 1,397 | 708 | 160 |
| Receivables | 309 | 297 | 12 | 2,973 | 535 |
| TOTAL | $636 | $1,171 | $1,416 | $3,693 | $718 |
| Non-Current Assets | |||||
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $636 | $1,171 | $1,416 | $3,693 | $718 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,537 | 4,312 | 2,100 | 3,606 | 2,100 |
| Accounts payable and accrued liabilities | 301 | 393 | 2,088 | 3,137 | 768 |
| Accrued Expenses | 212 | 173 | 104 | 66 | 28 |
| TOTAL | $5,850 | $5,977 | $4,292 | $6,808 | $2,896 |
| Non-Current Liabilities | |||||
| Long Term Debt | 500 | 704 | 2,878 | 2,316 | 2,291 |
| Deferred Revenues | 801 | 1,099 | N/A | N/A | N/A |
| TOTAL | $500 | $704 | $2,878 | $2,316 | $2,291 |
| Total Liabilities | $6,350 | $6,681 | $7,171 | $9,124 | $5,187 |
| Shareholders' Equity | |||||
| Common Shares | 15,883 | 15,883 | 15,883 | 15,755 | 15,755 |
| Retained earnings | -28,834 | -28,051 | -28,295 | -27,844 | -26,882 |
| TOTAL | $-5,713 | $-5,510 | $-5,754 | $-5,431 | $-4,469 |
| Total Liabilities And Equity | $636 | $1,171 | $1,416 | $3,693 | $718 |